within Pharmacolibrary.Drugs.ATC.B;

model B05AX02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AX02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Thrombocytes, also known as platelets, are cellular components of blood involved in hemostasis, leading to the formation of blood clots. Thrombocyte (platelet) concentrates are commonly used as blood products to prevent or treat bleeding in patients with low platelet counts, such as those with hematological diseases, cancer chemotherapy, or major surgery. As a 'drug', platelet transfusions are approved and widely used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>No traditional pharmacokinetic parameters (such as volume of distribution or clearance) are typically reported for thrombocyte transfusions in medical literature, because the product consists of viable cells rather than a single molecule. The pharmacokinetics are more related to platelet survival, recovery, and lifespan in recipient's circulation. Thus, standard PK parameters like volume of distribution or clearance are not applicable.</p><h4>References</h4><ol><li><p>Holm, M, et al., &amp; van der Linden, J (2019). The MOVEMENT Trial. <i>Journal of the American Heart Association</i> 8(2) e010152–None. DOI:<a href=&quot;https://doi.org/10.1161/JAHA.118.010152&quot;>10.1161/JAHA.118.010152</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30636504/&quot;>https://pubmed.ncbi.nlm.nih.gov/30636504</a></p></li><li><p>Scaradavou, A (2002). HIV-related thrombocytopenia. <i>Blood reviews</i> 16(1) 73–76. DOI:<a href=&quot;https://doi.org/10.1054/blre.2001.0188&quot;>10.1054/blre.2001.0188</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11914001/&quot;>https://pubmed.ncbi.nlm.nih.gov/11914001</a></p></li><li><p>Raggio, MJ, &amp; Morris, PE (2004). Drotrecogin alfa. <i>Drugs of today (Barcelona, Spain : 1998)</i> 40(6) 517–538. DOI:<a href=&quot;https://doi.org/10.1358/dot.2004.40.6.850484&quot;>10.1358/dot.2004.40.6.850484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15349131/&quot;>https://pubmed.ncbi.nlm.nih.gov/15349131</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AX02;
